Atrial fibrillation onset before heart failure or vice versa: what is worst? A nationwide register study

Jannik Pallisgaard, Anders M. Greve, Morten Lock-Hansen, Jens Jakob Thune, Emil Loldrup Fosboel, Richard B. Devereux, Peter M. Okin, Gunnar H. Gislason, Christian Torp-Pedersen, Casper N. Bang*

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

11 Citationer (Scopus)
12 Downloads (Pure)

Abstract

Aims
Atrial fibrillation (AF) and heart failure (HF) often coexist. However, whether AF onset before HF or vice versa is associated with the worst outcome remains unclear. A consensus of large studies can guide future research and preventive strategies to better target high-risk patients.

Methods and results
We included all Danish cases with the coexistence of AF and HF (2005–17) using nationwide registries. Patients were divided into three separate groups (i) AF before HF, (ii) HF before AF, or (iii) AF and HF diagnosed concurrently (±30 days). Adjusting landmark Cox analyses (index date was the time of the latter diagnosis of AF or HF) were used for evaluating the association of the three groups with a composite outcome of ischaemic stroke or death. Among a total of 49 042 patients included, 40% had AF before HF, 27% had HF before AF, and 33% had AF and HF diagnosed concurrently. The composite endpoint accrued more often in patients with HF before AF compared to the two other groups (<0.001), and this remained significant in the adjusted analyses with hazard ratios (95% confidence intervals) of 1.26 (1.22–1.30) compared to AF before HF. Finally, antihypertensive treatment, oral anticoagulants, amiodarone, statins, and AF ablation were associated with a lower hazard ratio of the composite endpoint (all < 0.001).

Conclusions
In this large Danish national cohort, diagnosis of HF before AF was associated with an increased absolute risk of death compared to AF before HF and AF and HF diagnosed concurrently. Antihypertensive treatment, oral anticoagulants, amiodarone, statins, and AF ablation may improve prognosis.
OriginalsprogEngelsk
TidsskriftEuropace
Vol/bind25
Udgave nummer2
Sider (fra-til)283-290
Antal sider8
ISSN1099-5129
DOI
StatusUdgivet - 2023

Bibliografisk note

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of the European Society of Cardiology.

Citationsformater